title: Efficacy of the S.M.A.R.T. Control vs. other stents for aortoiliac occlusive disease in contemporary clinical practice.
abstract: OBJECTIVE
  To compare the safety and efficacy of the S.M.A.R.T. Control stent vs. other stents in patients with symptomatic aortoiliac occlusive disease (AIOD) followed for up to 4 years.
  
  
  METHODS
  A subgroup analysis of data from a retrospective multicenter registry examined 2036 symptomatic patients (1659 men; mean age 71±8 years) who received stent-supported endovascular therapy for 2541 AIOD lesions between April 2005 and December 2009. The cohort was divided into the S.M.A.R.T. stent group (955 patients/1196 lesions) and the "other" stent group (1081 patients/1345 lesions). The main study outcomes of primary patency and event-free survival at 4 years were compared before and after propensity matching analysis. The rates for freedom from major amputation, surgical conversion, target lesion revascularization (TLR), and major adverse limb events were also assessed.
  
  
  RESULTS
  The S.M.A.R.T. Control stent group had greater frequency of critical limb ischemia (CLI), TASC C/D lesions, and chronic total occlusions. The mean follow-up was 25±17 months in the S.M.A.R.T. group vs. 29±19 months in the other stent group. After propensity matching, 4-year primary patency (86% vs. 76%, p<0.001) and freedom from adverse limb events (93% vs. 90%, p=0.04) were greater in the S.M.A.R.T. Control stent group, while event-free survival rates (75% vs. 77%, p=0.50) were similar between groups. Univariate subgroup analysis showed that use of the S.M.A.R.T. stent was associated with greater primary patency in patients with renal insufficiency (serum creatinine >1.5 mg/dL) and CLI.
  
  
  CONCLUSIONS
  After propensity matching analysis, the durability of the S.M.A.R.T. stent was superior to that of other stents, which might reflect differing design characteristics.
authors.affiliation: Cardiovascular Center, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan. iida.osa@gmail.com
authors.forename: Osamu
authors.initials: O
authors.lastname: Iida
authors.forename: Yoshimitsu
authors.initials: Y
authors.lastname: Soga
authors.forename: Mitsuyoshi
authors.initials: M
authors.lastname: Takahara
authors.forename: Daizo
authors.initials: D
authors.lastname: Kawasaki
authors.forename: Yasutaka
authors.initials: Y
authors.lastname: Yamauchi
authors.forename: Kenji
authors.initials: K
authors.lastname: Suzuki
authors.forename: Keisuke
authors.initials: K
authors.lastname: Hirano
authors.forename: Koshida
authors.initials: K
authors.lastname: Ryoji
authors.forename: Daisuke
authors.initials: D
authors.lastname: Kamoi
authors.forename: Junichi
authors.initials: J
authors.lastname: Tazaki
authors.forename: Michiaki
authors.initials: M
authors.lastname: Higashitani
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Shintani
authors.forename: Terutoshi
authors.initials: T
authors.lastname: Yamaoka
authors.forename: Shinya
authors.initials: S
authors.lastname: Okazaki
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Suematsu
authors.forename: Taketsugu
authors.initials: T
authors.lastname: Tsuchiya
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Miyashita
authors.forename: Norihiko
authors.initials: N
authors.lastname: Shinozaki
authors.forename: Hiroki
authors.initials: H
authors.lastname: Takahashi
authors.forename: Masaaki
authors.initials: M
authors.lastname: Uematsu
mesh_terms: D000368:Aged; D001018:Aortic Diseases / Q000601:surgery*; D001157:Arterial Occlusive Diseases / Q000601:surgery*; D057510:Endovascular Procedures / Q000379:methods*; D005260:Female; D006801:Humans; D007083:Iliac Artery / Q000601:surgery*; D008297:Male; D011474:Prosthesis Design; D012189:Retrospective Studies; D015607:Stents